Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia

ABSTRACT Objective The aim of this study was to compare the predictive validity of eight different adherence measures by studying the variability explained between each measure and hospitalization episodes among Medicaid-eligible persons diagnosed with schizophrenia on antipsychotic monotherapy. Met...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2009-09, Vol.12 (6), p.989-995
Hauptverfasser: Karve, Sudeep, BPharm, MS, Cleves, Mario A., PhD, Helm, Mark, MD, Hudson, Teresa J., PharmD, West, Donna S., RPh, PhD, Martin, Bradley C., PharmD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 995
container_issue 6
container_start_page 989
container_title Value in health
container_volume 12
creator Karve, Sudeep, BPharm, MS
Cleves, Mario A., PhD
Helm, Mark, MD
Hudson, Teresa J., PharmD
West, Donna S., RPh, PhD
Martin, Bradley C., PharmD, PhD
description ABSTRACT Objective The aim of this study was to compare the predictive validity of eight different adherence measures by studying the variability explained between each measure and hospitalization episodes among Medicaid-eligible persons diagnosed with schizophrenia on antipsychotic monotherapy. Methods This study was a retrospective analysis of the Arkansas Medicaid administrative claims data. Continuously eligible adult schizophrenia (ICD-9-CM = 295.**) patients on antipsychotic monotherapy were identified in the recruitment period from July 2000 through April 2004. Adherence rates to antipsychotic therapy in year 1 were calculated using eight different measures identified from the literature. Univariate and multivariable logistic regression models were used to prospectively predict all-cause and mental health-related hospitalizations in the follow-up year. Results Adherence rates were computed for 3395 schizophrenic patients with a mean age of 42.9 years, of which 52.5% (n = 1782) were females, and 52.8% (n = 1793) were white. The proportion of days covered (PDC) and continuous measure of medication gaps measures of adherence had equal C-statistics of 0.571 in predicting both all-cause and mental health-related hospitalizations. The medication possession ratio (MPR) continuous multiple interval measure of oversupply were the second best measures with equal C-statistics of 0.568 and 0.567 for any-cause and mental health-related hospitalizations. The multivariate adjusted models had higher C-statistics but provided the same rank order results. Conclusions MPR and PDC were among the best predictors of any-cause and mental health-related hospitalization, and are recommended as the preferred adherence measures when a single measure is sought for use with administrative claims data for patients not on polypharmacy.
doi_str_mv 10.1111/j.1524-4733.2009.00543.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754138579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1098301510602999</els_id><sourcerecordid>67681848</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5933-34add15cd656869a57f6b479ab80f7defbb32b11d4e5e047f0051936adab051f3</originalsourceid><addsrcrecordid>eNqNUsFu1DAUjBCIlsIvIJ_glGDHcRJLCKlsF4pURKXSXi3Hfm68JPFiJ22XD-C7cZoVSBygvvhJb2ZszUySIIIzEs-bTUZYXqRFRWmWY8wzjFlBs7tHyeHvxeM4Y16nFBN2kDwLYYMxLmnOniYHhBc4r1l-mPw89y5sQY32BtCV7KyWo3UDcgat7XU7ohNrDHgYRnSs23lQgD6DDJOHgIzz6DIAurVjG_e9HWwYvbwXW3XS9gGdyFEi2bvhGp3HRRQKC_xCtfaH27ZR0srnyRMjuwAv9vdRcvlh_XV1mp59-fhpdXyWKsYpTWkhtSZM6ZKVdcklq0zZFBWXTY1NpcE0Dc0bQnQBDHBRmegL4bSUWjZxMvQoeb3obr37PkEYRW-Dgq6TA7gpiIoVhNas4hH56p_IsiprUhf1f4E5rjCNdkdgvQBVtDx4MGLrbS_9ThAs5ljFRszpiTk9Mccq7mMVd5H6cv_G1PSg_xD3OUbA2wVwazvYPVhYXJ2u4xDp7xc6RO9vLHgRlJ2j1tbHbgjt7EM--e4vEdXFQijZfYMdhI2b_BCzFUSEXGBxMbdzLifBJc455_QXUMLcLw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20703402</pqid></control><display><type>article</type><title>Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>MEDLINE</source><source>Wiley Online Library</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Karve, Sudeep, BPharm, MS ; Cleves, Mario A., PhD ; Helm, Mark, MD ; Hudson, Teresa J., PharmD ; West, Donna S., RPh, PhD ; Martin, Bradley C., PharmD, PhD</creator><creatorcontrib>Karve, Sudeep, BPharm, MS ; Cleves, Mario A., PhD ; Helm, Mark, MD ; Hudson, Teresa J., PharmD ; West, Donna S., RPh, PhD ; Martin, Bradley C., PharmD, PhD</creatorcontrib><description>ABSTRACT Objective The aim of this study was to compare the predictive validity of eight different adherence measures by studying the variability explained between each measure and hospitalization episodes among Medicaid-eligible persons diagnosed with schizophrenia on antipsychotic monotherapy. Methods This study was a retrospective analysis of the Arkansas Medicaid administrative claims data. Continuously eligible adult schizophrenia (ICD-9-CM = 295.**) patients on antipsychotic monotherapy were identified in the recruitment period from July 2000 through April 2004. Adherence rates to antipsychotic therapy in year 1 were calculated using eight different measures identified from the literature. Univariate and multivariable logistic regression models were used to prospectively predict all-cause and mental health-related hospitalizations in the follow-up year. Results Adherence rates were computed for 3395 schizophrenic patients with a mean age of 42.9 years, of which 52.5% (n = 1782) were females, and 52.8% (n = 1793) were white. The proportion of days covered (PDC) and continuous measure of medication gaps measures of adherence had equal C-statistics of 0.571 in predicting both all-cause and mental health-related hospitalizations. The medication possession ratio (MPR) continuous multiple interval measure of oversupply were the second best measures with equal C-statistics of 0.568 and 0.567 for any-cause and mental health-related hospitalizations. The multivariate adjusted models had higher C-statistics but provided the same rank order results. Conclusions MPR and PDC were among the best predictors of any-cause and mental health-related hospitalization, and are recommended as the preferred adherence measures when a single measure is sought for use with administrative claims data for patients not on polypharmacy.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1111/j.1524-4733.2009.00543.x</identifier><identifier>PMID: 19402852</identifier><language>eng</language><publisher>Malden, USA: Elsevier Inc</publisher><subject>Adherence ; Adolescent ; Adult ; Antipsychotic Agents - therapeutic use ; Antipsychotic drugs ; Arkansas ; Drug Prescriptions - statistics &amp; numerical data ; Drug Utilization - statistics &amp; numerical data ; Female ; Hospitalization ; Humans ; Insurance Claim Reporting ; Internal Medicine ; Logistic Models ; Male ; Medicaid ; Medication Adherence - statistics &amp; numerical data ; Middle Aged ; pharmacy claims ; Schizophrenia ; Schizophrenia - drug therapy ; United States ; validation ; Young Adult</subject><ispartof>Value in health, 2009-09, Vol.12 (6), p.989-995</ispartof><rights>International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2009 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2009, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5933-34add15cd656869a57f6b479ab80f7defbb32b11d4e5e047f0051936adab051f3</citedby><cites>FETCH-LOGICAL-c5933-34add15cd656869a57f6b479ab80f7defbb32b11d4e5e047f0051936adab051f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1524-4733.2009.00543.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1098301510602999$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,3537,27901,27902,30977,45550,45551,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19402852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karve, Sudeep, BPharm, MS</creatorcontrib><creatorcontrib>Cleves, Mario A., PhD</creatorcontrib><creatorcontrib>Helm, Mark, MD</creatorcontrib><creatorcontrib>Hudson, Teresa J., PharmD</creatorcontrib><creatorcontrib>West, Donna S., RPh, PhD</creatorcontrib><creatorcontrib>Martin, Bradley C., PharmD, PhD</creatorcontrib><title>Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia</title><title>Value in health</title><addtitle>Value Health</addtitle><description>ABSTRACT Objective The aim of this study was to compare the predictive validity of eight different adherence measures by studying the variability explained between each measure and hospitalization episodes among Medicaid-eligible persons diagnosed with schizophrenia on antipsychotic monotherapy. Methods This study was a retrospective analysis of the Arkansas Medicaid administrative claims data. Continuously eligible adult schizophrenia (ICD-9-CM = 295.**) patients on antipsychotic monotherapy were identified in the recruitment period from July 2000 through April 2004. Adherence rates to antipsychotic therapy in year 1 were calculated using eight different measures identified from the literature. Univariate and multivariable logistic regression models were used to prospectively predict all-cause and mental health-related hospitalizations in the follow-up year. Results Adherence rates were computed for 3395 schizophrenic patients with a mean age of 42.9 years, of which 52.5% (n = 1782) were females, and 52.8% (n = 1793) were white. The proportion of days covered (PDC) and continuous measure of medication gaps measures of adherence had equal C-statistics of 0.571 in predicting both all-cause and mental health-related hospitalizations. The medication possession ratio (MPR) continuous multiple interval measure of oversupply were the second best measures with equal C-statistics of 0.568 and 0.567 for any-cause and mental health-related hospitalizations. The multivariate adjusted models had higher C-statistics but provided the same rank order results. Conclusions MPR and PDC were among the best predictors of any-cause and mental health-related hospitalization, and are recommended as the preferred adherence measures when a single measure is sought for use with administrative claims data for patients not on polypharmacy.</description><subject>Adherence</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic drugs</subject><subject>Arkansas</subject><subject>Drug Prescriptions - statistics &amp; numerical data</subject><subject>Drug Utilization - statistics &amp; numerical data</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Insurance Claim Reporting</subject><subject>Internal Medicine</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medicaid</subject><subject>Medication Adherence - statistics &amp; numerical data</subject><subject>Middle Aged</subject><subject>pharmacy claims</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>United States</subject><subject>validation</subject><subject>Young Adult</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNUsFu1DAUjBCIlsIvIJ_glGDHcRJLCKlsF4pURKXSXi3Hfm68JPFiJ22XD-C7cZoVSBygvvhJb2ZszUySIIIzEs-bTUZYXqRFRWmWY8wzjFlBs7tHyeHvxeM4Y16nFBN2kDwLYYMxLmnOniYHhBc4r1l-mPw89y5sQY32BtCV7KyWo3UDcgat7XU7ohNrDHgYRnSs23lQgD6DDJOHgIzz6DIAurVjG_e9HWwYvbwXW3XS9gGdyFEi2bvhGp3HRRQKC_xCtfaH27ZR0srnyRMjuwAv9vdRcvlh_XV1mp59-fhpdXyWKsYpTWkhtSZM6ZKVdcklq0zZFBWXTY1NpcE0Dc0bQnQBDHBRmegL4bSUWjZxMvQoeb3obr37PkEYRW-Dgq6TA7gpiIoVhNas4hH56p_IsiprUhf1f4E5rjCNdkdgvQBVtDx4MGLrbS_9ThAs5ljFRszpiTk9Mccq7mMVd5H6cv_G1PSg_xD3OUbA2wVwazvYPVhYXJ2u4xDp7xc6RO9vLHgRlJ2j1tbHbgjt7EM--e4vEdXFQijZfYMdhI2b_BCzFUSEXGBxMbdzLifBJc455_QXUMLcLw</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Karve, Sudeep, BPharm, MS</creator><creator>Cleves, Mario A., PhD</creator><creator>Helm, Mark, MD</creator><creator>Hudson, Teresa J., PharmD</creator><creator>West, Donna S., RPh, PhD</creator><creator>Martin, Bradley C., PharmD, PhD</creator><general>Elsevier Inc</general><general>Blackwell Publishing Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>7QJ</scope></search><sort><creationdate>200909</creationdate><title>Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia</title><author>Karve, Sudeep, BPharm, MS ; Cleves, Mario A., PhD ; Helm, Mark, MD ; Hudson, Teresa J., PharmD ; West, Donna S., RPh, PhD ; Martin, Bradley C., PharmD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5933-34add15cd656869a57f6b479ab80f7defbb32b11d4e5e047f0051936adab051f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adherence</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic drugs</topic><topic>Arkansas</topic><topic>Drug Prescriptions - statistics &amp; numerical data</topic><topic>Drug Utilization - statistics &amp; numerical data</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Insurance Claim Reporting</topic><topic>Internal Medicine</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medicaid</topic><topic>Medication Adherence - statistics &amp; numerical data</topic><topic>Middle Aged</topic><topic>pharmacy claims</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>United States</topic><topic>validation</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karve, Sudeep, BPharm, MS</creatorcontrib><creatorcontrib>Cleves, Mario A., PhD</creatorcontrib><creatorcontrib>Helm, Mark, MD</creatorcontrib><creatorcontrib>Hudson, Teresa J., PharmD</creatorcontrib><creatorcontrib>West, Donna S., RPh, PhD</creatorcontrib><creatorcontrib>Martin, Bradley C., PharmD, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karve, Sudeep, BPharm, MS</au><au>Cleves, Mario A., PhD</au><au>Helm, Mark, MD</au><au>Hudson, Teresa J., PharmD</au><au>West, Donna S., RPh, PhD</au><au>Martin, Bradley C., PharmD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2009-09</date><risdate>2009</risdate><volume>12</volume><issue>6</issue><spage>989</spage><epage>995</epage><pages>989-995</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>ABSTRACT Objective The aim of this study was to compare the predictive validity of eight different adherence measures by studying the variability explained between each measure and hospitalization episodes among Medicaid-eligible persons diagnosed with schizophrenia on antipsychotic monotherapy. Methods This study was a retrospective analysis of the Arkansas Medicaid administrative claims data. Continuously eligible adult schizophrenia (ICD-9-CM = 295.**) patients on antipsychotic monotherapy were identified in the recruitment period from July 2000 through April 2004. Adherence rates to antipsychotic therapy in year 1 were calculated using eight different measures identified from the literature. Univariate and multivariable logistic regression models were used to prospectively predict all-cause and mental health-related hospitalizations in the follow-up year. Results Adherence rates were computed for 3395 schizophrenic patients with a mean age of 42.9 years, of which 52.5% (n = 1782) were females, and 52.8% (n = 1793) were white. The proportion of days covered (PDC) and continuous measure of medication gaps measures of adherence had equal C-statistics of 0.571 in predicting both all-cause and mental health-related hospitalizations. The medication possession ratio (MPR) continuous multiple interval measure of oversupply were the second best measures with equal C-statistics of 0.568 and 0.567 for any-cause and mental health-related hospitalizations. The multivariate adjusted models had higher C-statistics but provided the same rank order results. Conclusions MPR and PDC were among the best predictors of any-cause and mental health-related hospitalization, and are recommended as the preferred adherence measures when a single measure is sought for use with administrative claims data for patients not on polypharmacy.</abstract><cop>Malden, USA</cop><pub>Elsevier Inc</pub><pmid>19402852</pmid><doi>10.1111/j.1524-4733.2009.00543.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2009-09, Vol.12 (6), p.989-995
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_miscellaneous_754138579
source Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Wiley Online Library; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Adherence
Adolescent
Adult
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Arkansas
Drug Prescriptions - statistics & numerical data
Drug Utilization - statistics & numerical data
Female
Hospitalization
Humans
Insurance Claim Reporting
Internal Medicine
Logistic Models
Male
Medicaid
Medication Adherence - statistics & numerical data
Middle Aged
pharmacy claims
Schizophrenia
Schizophrenia - drug therapy
United States
validation
Young Adult
title Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A46%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20Validation%20of%20Eight%20Different%20Adherence%20Measures%20for%20Use%20with%20Administrative%20Claims%20Data%20among%20Patients%20with%20Schizophrenia&rft.jtitle=Value%20in%20health&rft.au=Karve,%20Sudeep,%20BPharm,%20MS&rft.date=2009-09&rft.volume=12&rft.issue=6&rft.spage=989&rft.epage=995&rft.pages=989-995&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1111/j.1524-4733.2009.00543.x&rft_dat=%3Cproquest_cross%3E67681848%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20703402&rft_id=info:pmid/19402852&rft_els_id=1_s2_0_S1098301510602999&rfr_iscdi=true